Navigation Links
Cellceutix Discovers Drug Activates 'Guardian Angel p53' in Fight Against Leukemia
Date:3/7/2011

reated with Kevetrin took a median of 32 days to reach 1000 mm3 in volume whereas control mice took only 15 days, resulting in a Tumor Growth Delay of 110%.  In addition, after Kevetrin treatment, the tumors in 14% of the mice completely regressed for a period of 3 weeks. This was achieved with no significant weight loss in the animals. This represents more potent anti-tumor activity compared to historical data with standard leukemia chemotherapies, Vincristine or Daunorubicin, in a human xenograft model, e.g., Vincristine (0.2 mg/kg every other day for 1 week) reduced tumor volumes by 55% and Daunorubicn (1 mg/kg every other day for 2 weeks) reduced tumor volume by 30% in the MOLM-13 acute myeloid leukemia xenograft model (Yang 2007 Blood 110:2034).

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, "Kevetrin continues to exceed our original expectations as a possible new cancer therapy. Dr. Frei is amongst the most elite cancer researchers in the history of the disease.  For Kevetrin to impress him is really saying something about the possibilities of this novel compound."

Cellceutix has been notified by its  formulation vendor that production is scheduled to begin this week to produce Kevetrin in the dosage form for planned clinical trials. The Company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in May 2011, with human trials to begin thereafter.

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

This Press Rele
'/>"/>

SOURCE Cellceutix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity in Study
2. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
3. Video: New Research Discovers Independent Brain Networks Control Human Walking
4. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
9. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
10. deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
11. deCODE Discovers Four New Risk Factors for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ) ... ended June 28, 2014. Third Quarter Financial ... to $632.6 million, reflecting operational growth of 0.5% and ... same period in the prior year. , Revenues ... Breast Health revenues grew 3.5%. , GYN Surgical ...
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... CryoLife, Inc. (NYSE: CRY), a leading medical device and ... announced today that its Board of Directors has approved ... of $0.03 per share of common stock outstanding.  The ... paid on September 19, 2014 to all common stockholders ... date for the quarterly dividend is September 10, 2014.  ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3
... AuraSense Therapeutics, a biopharmaceutical company commercializing spherical ... and chemo-therapeutics for a variety of diseases, ... for cardiovascular disorders, has closed its Series ... a subsidiary of Abbott.  Other key individual ...
... 2011 /PRNewswire-Asia/ -- The Ministry of Health and ... Industry Development Institute (President Ko Kyung-hwa) launched a ... foreign patients by designating 38 tasks, including seven ... for medical injuries and granting permission for drug ...
Cached Medicine Technology:AuraSense Therapeutics Secures Series B Equity Investment 2Medical Korea's Medical Policy Improvement Project for Foreign Patients 2
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... New York (PRWEB) July 30, 2014 ... uncontrollable brain bleeding has filed a Xarelto lawsuit ( ... the blood thinner, Bernstein Liebhard LLP reports. According to ... for the District of Vermont on July 25th, the ... when he suffered an irreversible brain bleed that ultimately ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... just received a major grant from the National Center ... the National Institutes of Health (NIH) and lead Federal ... new grant creates a Center of Excellence for Research ... will focus on Alzheimers disease. The new Center has ...
... 2007. A report to be published in an upcoming ... for urgent attention to the politically sensitive issue of border ... in the face of a catastrophic flu pandemic . ... of a strain of avian influenza A (HN51) in Northern ...
... today,announced it received a $250,000 grant from the ... support services. The university will use the ... professions. The newly created program, named the ... help the university recruit and support,Hispanic women in ...
... for Eating Disorders Reports Eating Disorders Develop or ... Worsen Upon Returning ... Eating Disorders, http://www.remudaranch.com, the nation,s leading eating disorder treatment,center, ... A majority of eating disorders begin at ages 14 and ...
... Governor,Arnold Schwarzenegger held a press conference announcing ... state legislature aimed at producing,reforms to California,s ... Policies Institute issued the following statement:, ... solve California,s,health care crisis," said Jill Jenkins, ...
... YORK, Oct. 10 Philip K. Howard, Chair of Common,Good, ... in response to a recent study on health courts that ... "The American Association of Justice (formerly known as the Association ... a study that it commissioned on the ...
Cached Medicine News:Health News:Mount Sinai recognized as Center of Excellence for Research in Alzheimer's disease 2Health News:Report highlights inadequate pandemic planning as a threat to EU security 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 2Health News:Wal-Mart Foundation Provides Brenau University $250,000 Health Care scholarships Grant for Hispanic Women 3Health News:Going Back to School Can Trigger Eating Disorders 2Health News:Going Back to School Can Trigger Eating Disorders 3Health News:Common Good Responds to a Trial Bar Study Opposing Health Courts 2
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
Intended for the quantitative determination of creatinine in serum, plasma, or urine. Reaction: Endpoint. Wavelength: 340 nm. Linearity: 10 mg/dL (880 mol/L). Two vials, dry powder reagents....
For the quantitative determination of creatine kinase-MB in serum. Kinetic Reaction measured at 340 nm. Linearity: 700 IU/L at 37C....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
Medicine Products: